extended postimplantation dual antiplatelet therapy — Competitive Intelligence Brief

extended postimplantation dual antiplatelet therapy (extended postimplantation dual antiplatelet therapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet therapy combination. Area: Cardiovascular.

marketed Antiplatelet therapy combination Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor) Cardiovascular Small molecule

Target snapshot

extended postimplantation dual antiplatelet therapy (extended postimplantation dual antiplatelet therapy) — National Institute of Cardiology, Warsaw, Poland. Extended dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) prevents stent thrombosis and reduces cardiovascular events by inhibiting platelet aggregation for a prolonged period after coronary stent implantation.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
extended postimplantation dual antiplatelet therapy TARGET	extended postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy combination	Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor)
DAPT strategy	DAPT strategy	Assistance Publique - Hôpitaux de Paris	phase 3	Antiplatelet therapy combination	P2Y12 receptor and cyclooxygenase (COX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet therapy combination class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. National Institute of Cardiology, Warsaw, Poland · 1 drug in this class